Cytokinetics, Incorporated
Cytokinetics, Incorporated (CYTK) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · CYTK · as of Sep 30, 2025
Ownership Breakdown
427
Institutional Holders
▲ 80 vs Q2
$8.78B
Total Inst. Value
▲ $4.23B vs Q2
124.43M
Shares Outstanding
freeFloat 95.76%
141.28M
13F Shares Held
▲ 3.26M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
CYTK largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. pharmaceutical preparations | 19.08M | 15.97% | 15.97% | $1.05T | Nov 14, 2025 | ▲ 1.48M |
BLACKROCK, INC. pharmaceutical preparations | 15.53M | 13.00% | 13.00% | $853.30B | Nov 12, 2025 | ▼ 152.1K |
FMR LLC pharmaceutical preparations | 13.09M | 10.96% | 10.96% | $719.52B | Nov 13, 2025 | ▲ 1.82M |
VANGUARD GROUP INC pharmaceutical preparations | 11.86M | 9.93% | 9.93% | $651.65B | Nov 7, 2025 | ▼ 127.0K |
WELLINGTON MANAGEMENT GROUP LLP pharmaceutical preparations | 7.41M | 6.20% | 6.20% | $407.17B | Nov 14, 2025 | ▼ 419.1K |
TUDOR INVESTMENT CORP ET AL pharmaceutical preparations | 6.00M | 5.02% | 5.02% | $6.86B | Nov 14, 2025 | NEW |
STATE STREET CORP pharmaceutical preparations | 5.62M | 4.70% | 4.70% | $308.73B | Nov 14, 2025 | ▼ 755.4K |
DEEP TRACK CAPITAL, LP pharmaceutical preparations | 4.30M | 3.60% | 3.60% | $236.33B | Nov 14, 2025 | ▲ 650.0K |
BANK OF AMERICA CORP /DE/ pharmaceutical preparations | 3.06M | 2.56% | 2.56% | $168.28B | Feb 3, 2026 | ▲ 416.2K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 3.04M | 2.54% | 2.54% | $167.11B | Nov 12, 2025 | ▲ 45.8K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
29
Increased
+11.20M shares2
New Positions
first time holders17
Decreased
−6.75M shares0
Sold Out
fully exitedNet shares change (top 50)
+4.45M
+11.20M / −6.75M
Net new holders
+14
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
CYTK insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
35
Buy transactions
31
Sell transactions
1.13
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kaye Edward M. MD director | Jun 1, 2026 | Sale | 2,933 | $76.09 | $223.2K | 10.3K | Form 4 ↗ |
Callos Andrew EVP, Chief Commercial Officer | Jun 1, 2026 | Sale | 15,000 | $74.08 | $1.11M | 58.6K | Form 4 ↗ |
PARSHALL B LYNNE director | Jun 1, 2026 | Sale | 5,000 | $74.08 | $370.4K | 15.8K | Form 4 ↗ |
Blum Robert I President & CEO | May 27, 2026 | Sale | 7,500 | $77.21 | $579.1K | 392.8K | Form 4 ↗ |
Bhanji Muna director | May 27, 2026 | Award | 2,851 | — | — | 26.4K | Form 4 ↗ |
Bhanji Muna director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Daly James M director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Daly James M director | May 27, 2026 | Award | 2,851 | — | — | 3.2K | Form 4 ↗ |
Harrington Robert Arthur director | May 27, 2026 | Award | 2,851 | — | — | 21.8K | Form 4 ↗ |
Harrington Robert Arthur director | May 27, 2026 | Award | 4,301 | $77.15 | $331.8K | 4.3K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cytokinetics, Incorporated (CYTK) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 4.24%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cytokinetics, Incorporated is T. ROWE PRICE INVESTMENT MANAGEMENT, INC., holding approximately 19.08 million shares — equal to 15.97% of outstanding shares — as of September 30, 2025.
A total of 427 institutional investors currently hold CYTK stock, with a combined institutional value of approximately $8.78 billion as of the most recent 13F filing period.
Frequently asked questions
CYTK ownershipCytokinetics, Incorporated (CYTK) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is T. ROWE PRICE INVESTMENT MANAGEMENT, INC. with a 15.97% stake. Company insiders hold 4.24%. Data sourced from SEC Form 13F as of September 30, 2025.